Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and response

Ann Oncol. 1994 Feb;5(2):133-9. doi: 10.1093/oxfordjournals.annonc.a058764.

Abstract

Patients and methods: Twenty-one patients with metastatic ovarian cancer with minimal residual disease confined to the peritoneal cavity, were treated with intraperitoneal-administered carboplatin. Carboplatin was added to 2 liters of fluid and given via a Tenckoff-catheter. A dwell-time of 4 hours was allowed. After removal of fluid the amount of recovered carboplatin was determined.

Results: It appeared that the median recovery of carboplatin was 25.5% (range 2%-56%). There was a great interpatient variability of carboplatin recovery but it was relatively constant during consecutive courses.

Conclusions: Optimal dosing of intraperitoneal-administered carboplatin with a dwell-time is not possible because of the differences in recovery. This manifested itself in the fact that the absorbed dose, as well as a calculated Area Under the concentration versus time Curve (AUC), were much better related to toxicity than the administered dose.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Aged
  • Blood Cells / drug effects
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Carboplatin / therapeutic use*
  • Female
  • Humans
  • Injections, Intraperitoneal
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Time Factors

Substances

  • Carboplatin